RecruitingPhase 1NCT07148089
Cardiovascular
Catecholaminergic Polymorphic Ventricular Tachycardia
Also known as CPVT, catecholaminergic VT, RYR2 channelopathy
Catecholaminergic Polymorphic Ventricular Tachycardia is a severe inherited arrhythmia syndrome in which adrenergic stimulation during exercise or emotional stress triggers bidirectional or polymorphic ventricular tachycardia, leading to sy
ORPHA:3286 ↗Gene RYR2Gene CASQ2Prevalence 1 per 10,000Onset Childhood or adolescenceAutosomal dominant (RYR2); autosomal recessive (CASQ2)
7
studies recruiting now
as of 7 Sept 2026
18
studies registered in total
as of 7 Sept 2026
8
countries with a recruiting site
as of 7 Sept 2026
4 Dec 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT06658899
A Phase 2 Study of CRD-4730 in CPVT
RecruitingNCT06546137
National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
RecruitingPhase 2NCT07263139
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
RecruitingNCT02824822
Genetic Markers of Cardiovascular Disease in Epilepsy
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 7 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Catecholaminergic Polymorphic Ventricular Tachycardia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: SADS Foundation Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic Polymorphic Ventricular Tachycardia is a severe inherited arrhythmia syndrome in which adrenergic stimulation during exercise or emotional stress triggers bidirectional or polymorphic ventricular tachycardia, leading to syncope and sudden cardiac death in structurally normal hearts. Mutations in RYR2, encoding the cardiac ryanodine receptor responsible for intracellular calcium release during excitation-contraction coupling, account for the majority of cases, with recessive mutations in CASQ2 (calsequestrin 2) responsible for a smaller proportion. The arrhythmia is highly reproducible on exercise stress testing, which is both the key diagnostic tool and a monitoring method used in clinical trials.
Common clinical features
Exercise or emotion-triggered syncope, often in childhoodBidirectional or polymorphic ventricular tachycardia on stress testingSudden cardiac arrest, frequently as the first manifestationPalpitations during physical activityNormal resting ECG and normal cardiac structure on imagingVentricular ectopy triggered at predictable heart rate thresholdsFamily history of exercise-related sudden deathSeizures misattributed to epilepsy in some children
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Catecholaminergic Polymorphic Ventricular Tachycardia. Not eligibility rules; those are set by each study.
- Exercise stress testing is the definitive diagnostic tool and is used as a primary outcome measure in CPVT trials; a baseline graded exercise test with continuous ECG monitoring is typically required.
- Genetic confirmation of RYR2 or CASQ2 pathogenic variants is important; given the implications for family members, cascade genetic testing should be performed before trial screening.
- Current treatment with beta-blockers and flecainide is standard of care; many trials require patients to be on maximally tolerated medical therapy before enrolment, so document dosing history.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).